Heart最新文献

{"title":"Coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy-associated genetic variants: a multicentre case-control study.","authors":"Valentina Alice Rossi, Matteo Palazzini, Enrico Ammirati, Alessio Gasperetti, Martin Grubler, Corinna Brunckhorst, Robert Manka, Andreas Giannopoulos, Felix C Tanner, Argelia Medeiros-Domingo, Piero Gentile, Manuela Bramerio, Dörthe Schmidt, Claudio Tondo, Andreas J Flammer, Frank Ruschitzka, Firat Duru, Ardan Muammer Saguner","doi":"10.1136/heartjnl-2024-324525","DOIUrl":"10.1136/heartjnl-2024-324525","url":null,"abstract":"<p><strong>Background: </strong>Cardiac sarcoidosis (CS) is a chronic inflammatory disease characterised by non-caseating granulomas, while arrhythmogenic cardiomyopathy (ACM) is a genetic condition mainly affecting desmosomal proteins. The coexistence of CS and genetic variants associated with ACM is not well understood, creating challenges in diagnosis and management. This study aimed to describe the clinical, imaging and genetic features of patients with both conditions.</p><p><strong>Methods: </strong>This was a multicentre retrospective case-control study involving three groups of patients: those with biopsy-proven CS and pathogenic or likely pathogenic genetic variants linked to ACM (n=5); patients with genetic variants but no CS (n=5); and patients with CS without genetic variants (n=5). Clinical data, including symptoms, electrocardiographic findings and imaging results from echocardiography, cardiac magnetic resonance and positron-emission tomography, were analysed.</p><p><strong>Results: </strong>Patients with CS and genetic variants were more likely to exhibit atrioventricular block (100%), PR prolongation (204 ms vs 160 ms) and paroxysmal atrial fibrillation (80%) compared with those with genetic variants alone (0% for both). Imaging findings showed a higher prevalence of septal involvement in patients with both conditions (80%) than in those with genetic variants alone (20%). No significant differences were observed between patients with CS and genetic variants and those with CS without genetic variants. The genetic variants identified included variants in PKP2 (40%), DSG2 (20%), DSP (20%) and TTN (20%).</p><p><strong>Conclusions: </strong>The coexistence of CS and ACM-associated genetic variants is associated with distinct clinical features, including PR prolongation, AVB1°, septal involvement and paroxysmal atrial fibrillation. These findings emphasise the need to evaluate for CS in individuals with ACM and associated genetic variants who present with conduction abnormalities or septal involvement, guiding tailored diagnostic and therapeutic strategies.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":"480-486"},"PeriodicalIF":5.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention.","authors":"Cheng Wang, Nadira Hamid, Vinayak Bapat, Joao L Cavalcante, John R Lesser, Evan Walser-Kuntz, Larissa Stanberry, Maurice Enriquez-Sarano, Paul Sorajja","doi":"10.1136/heartjnl-2024-325194","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325194","url":null,"abstract":"<p><strong>Background: </strong>Tricuspid regurgitation (TR) progression following left-sided valvular heart disease (VHD) correction is a critical clinical concern. This study aimed to determine the incidence, predictors and outcomes of TR progression in a contemporary cohort.</p><p><strong>Methods: </strong>We analysed 1644 patients (mean age 73 years, 62% men) without severe TR who underwent surgical or transcatheter treatment for aortic or mitral disease between 2014 and 2018. TR progression was defined as an increase in TR grade to moderate or severe on follow-up echocardiography.</p><p><strong>Results: </strong>At 5 years, TR progression incidence was 12.0% (95% CI 10.5% to 13.7%). Baseline factors associated with TR progression included older age, female sex, atrial fibrillation, prior pacemaker implantation and larger tricuspid annular diameter (TAD). The relationship between TAD and TR progression was linear (HR 1.08; 95% CI 1.04 to 1.11; p<0.001), with sex differences mitigated by indexing TAD to body surface area. TR progression was associated with increased all-cause mortality (adjusted HR 2.77; 95% CI 2.16 to 3.56; p<0.001) and a combined endpoint of death or heart failure hospitalisation (adjusted HR 2.91; 95% CI 2.21 to 3.82; p<0.001).</p><p><strong>Conclusions: </strong>TR progression is common after left-sided VHD correction and is associated with adverse outcomes. Indexing TAD to body surface area mitigates sex differences in risk assessment. These findings suggest that lower thresholds for prophylactic tricuspid intervention may be warranted in high-risk patients.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk and management of cardiac disease in kidney and liver transplant recipients.","authors":"Gautam R Shroff, Mina M Benjamin, Janani Rangaswami, Krista L Lentine","doi":"10.1136/heartjnl-2024-324796","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-324796","url":null,"abstract":"<p><p>Organ transplantation is the treatment of choice for individuals with kidney failure requiring kidney replacement therapy, as well as for those with end-stage liver disease. Despite the significant reduction in long-term morbidity and mortality with transplantation, kidney and liver allograft recipients remain at high risk for cardiovascular disease (CVD) and premature death from cardiovascular causes. This heightened risk is represented across all phenotypes of CVD, including coronary heart disease, heart failure, arrhythmias, valvulopathies and pulmonary hypertension. Pre-existing vascular risk factors for CVD, coupled with superimposed cardiovascular-kidney-metabolic derangements after transplantation, driven at least in part by post-transplant weight gain, immunosuppressive therapies and de novo risk factors such as dyslipidaemia and diabetes, coalesce to increase total CVD risk. In this review, we summarise pathophysiological considerations for both the short- and long-term increase in CVD risk following kidney/liver transplantation. We review the different phenotypes of CVD, with unique considerations for post-transplant care in this patient population. Finally, we highlight the need for awareness about long-term CVD risk and a multidisciplinary approach to managing organ-specific CVD risk in kidney and liver transplant patients.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation in patients with low-burden atrial fibrillation: new evidence focussing on device-detected AF.","authors":"Nina Becher, Andreas Metzner, Paulus Kirchhof","doi":"10.1136/heartjnl-2024-324848","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-324848","url":null,"abstract":"<p><p>Stroke, one of the most severe complications of atrial fibrillation (AF), can be prevented by oral anticoagulants in patients with ECG-documented AF and clinical stroke risk factors. Recent controlled trials suggest that reducing the burden of AF, that is, the time spent in AF, can reduce the risk of stroke. Furthermore, stroke rate was slightly lower than anticipated in controlled trials of anticoagulation in screening-detected AF, and substantially lower than expected in patients with device-detected atrial fibrillation (DDAF) and after AF ablation. These data suggest that AF burden modulates the risk of stroke in patients with AF. Based on their high AF burden in observational datasets, anticoagulation remains the default therapy in patients with ECG-documented AF. However, AF burden reduction using rhythm-control therapies emerges as a new treatment strategy for stroke prevention, and there may be a group of patients with such a low burden of AF, for example, patients with DDAF, that the risks of current anticoagulation therapies outweigh their stroke-preventing effects. Patients with DDAF in the absence of ECG-documented AF and without vascular disease appear to be at low risk of thromboembolic events. In patients with DDAF, shared decision-making that considers the presence of vascular disease, potentially the burden of AF if it is very high, and patient preferences currently emerges as good clinical care. More data are needed to robustly define the complex relations between AF burden, phenotypes and stroke risk.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.","authors":"Rory Maclean, Yang Chen, R Thomas Lumbers, Anoop Dinesh Shah","doi":"10.1136/heartjnl-2024-325132","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325132","url":null,"abstract":"<p><strong>Background and aims: </strong>Mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalisation in heart failure with reduced ejection fraction (HFrEF) but are underused, despite recommendation in key guidelines. Identifying the factors contributing to underuse and addressing adherence are key components of a learning health system. We aimed to evaluate MRA prescription in people with HFrEF who would benefit, based on the UK National Institute for Health and Care Excellence (NICE) HFrEF guideline.</p><p><strong>Methods: </strong>We used clinical code lists to identify people with HFrEF in primary care electronic health record (EHR) data from The Health Improvement Network database. For each calendar year 2014-2020, we identified individuals who met the NICE guideline criteria for MRA therapy. We fitted mixed effects logistic regression models to determine the factors contributing to MRA prescription.</p><p><strong>Results: </strong>Among 24 135 people with HFrEF studied between 2014 and 2020, 12 150 person-years were eligible for MRA treatment. The MRA prescription rate increased from 41% to 55%. MRA prescription was inversely associated with age (OR per 1 SD, 95% CI) (0.02 (0.01, 0.03)), increasing glomerular filtration rate (0.37 (0.25, 0.55)), hypertension (0.21 (0.40, 0.78)) and prescription of antihypertensives (0.03 (0.02, 0.07)). MRA prescription was associated with male gender (6.31 (3.20, 12.4)), dilated cardiomyopathy (25.9 (7.48, 89.4)), calendar year (2.17 (1.85, 2.54) per year after study start) and prescription of sacubitril/valsartan (214 (56, 823)).</p><p><strong>Conclusions: </strong>MRAs are underused in people with HFrEF in the UK. Although prescribing increased between 2014 and 2020, half of the cohort still did not receive the therapy. Older age, gender, comorbidities and co-prescriptions were linked to MRA underuse. Understanding the factors contributing to underprescribing at a population level should be used to inform quality improvement strategies.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional and national epidemiology of myocarditis: health inequalities, risk factors and forecasted burden based on the Global Burden of Disease Study 2021.","authors":"Changjun Li, Kun Xu, Aijia Du, Ningning Fu, Zhaolong Xu, Qinghua Chang","doi":"10.1136/heartjnl-2024-325523","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325523","url":null,"abstract":"<p><strong>Background: </strong>Myocarditis is a global epidemic that causes various medical conditions associated with an increased incidence and death numbers. This study aimed to investigate the trends in myocarditis-associated incidence, mortality, and disability-adjusted life-years (DALYs) with health inequalities, risk factors, and predict the disease burden, thereby mitigating the health hazards of myocarditis.</p><p><strong>Methods: </strong>This was a modelling study that used data from the Global Burden of Diseases 2021, from which myocarditis was included in the analysis. Incidence, death, DALYs, age-standardised incidence rate (ASIR), age-standardised mortality rate (ASMR), age-standardised DALYs rate (ASDR), cases change, corresponding estimated annual percentage change (EAPC), Slope Inequality of Index (SII) and Concentration Index were analysed.</p><p><strong>Results: </strong>From 1990 to 2021, incidence and death cases increased by 66.88% and 45.94%, respectively. The myocarditis-associated incidence and death cases increased in all five sociodemographic index (SDI) regions. Among the five SDI regions, the High SDI region had the highest myocarditis-associated ASIR with the least ASMR and ASDR in 2021. Regionally, Central Asia had the largest increase in EAPC of ASIR, ASMR and ASDR. Among 204 countries, Japan had the highest ASIR in 2021 and Romania had the highest ASMR and ASDR. Between 1990 and 2021, the SII and Concentration Index for DALYs have shown declining trends. The extreme temperatures were major contributors to the burden of myocarditis during 1990-2021. The projections suggested that the myocarditis-related global number of new cases and death would increase over the next 15 years. There may be upward trends in people of 15+of incidence number and 40+of death and DALYs number.</p><p><strong>Conclusions: </strong>Myocarditis is an increasing global health challenge with rising incidence and death. Management of extreme temperatures remains a major challenge. The number of incidence, death and DALYs in different age groups would continue to grow over the next 15 years. Therefore, measures should be taken to target risk factors and high-risk groups.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updating the Scottish national cardiovascular risk score: ASSIGN version 2.0.","authors":"Paul Welsh, Dorien M Kimenai, Mark Woodward","doi":"10.1136/heartjnl-2024-324852","DOIUrl":"10.1136/heartjnl-2024-324852","url":null,"abstract":"<p><strong>Background: </strong>The Assessing cardiovascular risk using Scottish Intercollegiate Guidelines Network (ASSIGN) risk score, developed in 2006, is used in Scotland for estimating the 10-year risk of first atherosclerotic cardiovascular disease (ASCVD). Rates of ASCVD are decreasing, and an update is required. This study aimed to recalibrate ASSIGN (V.2.0) using contemporary data and to compare recalibration with other potential approaches for updating the risk score.</p><p><strong>Methods: </strong>Data from Scotland-resident participants from UK Biobank (2006-2010) and the Generation Scotland Scottish Family Health Study (2006-2010), aged 40-69 and without previous ASCVD, were used for the derivation of scores. External evaluation was conducted on UK Biobank participants who were not residents of Scotland. The original ASSIGN predictor variables and weights formed the basis of the new sex-specific risk equation to predict the 10-year risk of ASCVD. Different approaches for updating ASSIGN (recalibration, rederivation and regression adjustment) were tested in the evaluation cohort.</p><p><strong>Results: </strong>The original ASSIGN score overestimated ASCVD risk in the evaluation cohort, with median predicted 10-year risks of 10.6% for females and 15.1% for males, compared with observed risks of 6% and 11.4%, respectively. The derivation cohort included 44 947 (57% females and a mean age of 55) participants. The recalibrated score, ASSIGN V.2.0, improved model fit in the evaluation cohort, predicting median 10-year risk of 4% for females and 8.9% for males. Similar improvements were achieved using the regression-adjusted model. Rederivation of ASSIGN using new beta coefficients offered only modest improvements in calibration and discrimination beyond simple recalibration. At the current risk threshold of20% 10-year risk, the original ASSIGN equation yielded a positive predictive value (PPV) of 16.3% and a negative predictive value (NPV) of 94.4%. Recalibrated ASSIGN V.2.0 showed similar performance at a 10% threshold, with a PPV of 16.8% and an NPV of 94.6%.</p><p><strong>Conclusions: </strong>The recalibrated ASSIGN V.2.0 will give a more accurate estimation of contemporary ASCVD risk in Scotland.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving insights into VEGFI cardiotoxicity: past challenges, present findings and future opportunities.","authors":"Kenya Kusunose","doi":"10.1136/heartjnl-2025-326107","DOIUrl":"https://doi.org/10.1136/heartjnl-2025-326107","url":null,"abstract":"","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.","authors":"Christopher J Love, Joshua Lampert, David Huneycutt, Dan L Musat, Mahek Shah, Jorge E Silva Enciso, Bryan Doherty, James L Gentry, Michael D Kwan, Ethan C Carter, Vivek Y Reddy","doi":"10.1136/heartjnl-2024-325608","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325608","url":null,"abstract":"<p><strong>Background: </strong>Hypertrophic cardiomyopathy (HCM) is often underdiagnosed. Artificial intelligence (AI)-based notification of HCM suspicion on a 12-lead ECG has been proposed to assist patient identification and evaluation. However, there has been no study to date to assess clinical implementation of this approach.</p><p><strong>Methods: </strong>In an open-label, multicentre prospective cohort study, Viz HCM (Viz.ai)-an AI-ECG software alerting of suspected HCM-was implemented at five healthcare systems between January and December 2023 to identify patients >18 years of age without prior HCM diagnosis. The coprimary endpoints were the percentage of HCM-suspected cases viewed by users and the types of follow-up actions. Additional outcome measures included the time to follow-up, demographic characteristics of enrolled patients and follow-up outcomes.</p><p><strong>Results: </strong>Out of 145 848 patients screened with algorithm-compliant ECGs, 4348 (3%) were alerted for suspected HCM. Users viewed 69% (3017/4348) of AI-suspected HCM cases. 217 patients met the study criteria and were enrolled with broad representation across racial and ethnic groups-including 23% Black, 9% Asian and 12% Hispanic or Latino. Of the enrolled patients, 182 (84%) had an indication for a total of 243 follow-up actions. The median (interquartile) time from ECG to diagnostic imaging indicating HCM was 7.5 (1.0-37.2) days. From the 217 enrolled patients, 17 (7.8%) were newly diagnosed with HCM-8 inpatient and 9 outpatient. During the study, deployment of an optimised algorithm operating point helped reduce the alert percentage of algorithm-screened patients from 4.4% (2097/47868) to 2.3% (2251/97980), p<0.0001, with no difference in the enrolment rate by alerts reviewed.</p><p><strong>Conclusion: </strong>An AI-based ECG device for HCM can be implemented successfully in a variety of clinical workflows to help identify new patients with HCM. Future study is warranted to assess scalability and comparisons to standard of care.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating pulmonary function testing with cardiopulmonary exercise testing for enhanced stratification in hypertrophic cardiomyopathy.","authors":"Robin Willixhofer, Massimo Mapelli, Nikita Baracchini, Nicola Campana, Teresa Maria Capovilla, Alessandro Nava, Elisabetta Salvioni, Carlo Vignati, Jeness Campodonico, Filippo Maria Rubbo, Damiano Magrì, Beatrice Pezzuto, Irene Mattavelli, Arianna Galotta, Nicolò Capra, Carriere Cosimo, Irena Tavčar, Maddalena Rossi, Christian Cadeddu, Marco Merlo, Gianfranco Sinagra, Piergiuseppe Agostoni","doi":"10.1136/heartjnl-2025-325737","DOIUrl":"https://doi.org/10.1136/heartjnl-2025-325737","url":null,"abstract":"<p><strong>Background: </strong>Cardiopulmonary exercise testing (CPET) is essential for assessing patients with hypertrophic cardiomyopathy (HCM), but the role of pulmonary function testing (PFT) in refining patient stratification remains underexplored. This study investigates the relationship between PFT and CPET parameters in patients with HCM.</p><p><strong>Methods: </strong>In this prospective two-centre study, 102 clinically stable patients with HCM underwent PFT and CPET. Spearman's correlation and multiple linear regression were used to assess relationships between PFT (forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV_₁)) and CPET variables, adjusting for confounders.</p><p><strong>Results: </strong>Patients exhibited preserved lung function (mean FVC: 90.7%; FEV₁: 92.5%). Strong correlations were observed between PFT and CPET metrics, including peak VO_₂ (FVC: r=0.649, p<0.001; FEV_₁: r=0.691, p<0.001) and peak ventilation (FVC: r=0.682, p<0.001; FEV_₁: r=0.688, p<0.001). Regression analysis confirmed independent associations between PFT and CPET performance (all p<0.001).</p><p><strong>Conclusion: </strong>PFT metrics strongly correlate with CPET parameters in HCM, suggesting that PFT could complement CPET for a more comprehensive assessment of exercise capacity and patient stratification.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}